Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine

ConclusionspwPMS with detectable disease activity (MRI, elevated NfL) should be considered for DMT. NfL appears to be a sensitive index of treatment effect in pwPMS, and may be a useful outcome in clinical trials targeting this patient group. Over and above its licensed indication (relapsing MS), cladribine may be an effective treatment option for pwPMS.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research